MDT
Another haircut, same haircut line
Truist took another swipe at Medtronic’s price target, lowering it to $95 from $103 while leaving the rating at Hold. That’s not a dramatic “run for the hills” call — but it is the kind of incremental pessimism that can keep a stock stuck in neutral, like a car with the parking brake half on.
What this means for your money
When a big-name medical devices company keeps collecting target cuts, the market tends to hear one thing: expectations are still too rosy. Medtronic isn’t being accused of falling apart; it’s more of a “prove it first” story, where analysts want cleaner growth and better execution before they start throwing confetti.
The analyst tape keeps getting longer
Truist’s note lands in a busy week for Medtronic watchers:
- Baird just nudged its target to $93 from $92 and stayed Neutral
- Mizuho cut its target to $120 from $125 but kept Outperform
- Evercore ISI trimmed to $106 from $108 and still likes it
- Citigroup lowered to $110 from $117 while sticking with Buy
So the chorus isn’t screaming disaster. It’s more like a room full of people politely lowering their hand at the same time.
Big picture
For investors, this is less about one analyst’s math and more about the vibe shift around Medtronic: decent business, but not enough spark to get the market to pay up. Until the company shows stronger growth or a cleaner path to upside, these little target cuts can keep acting like headwinds in dress shoes.